CAMBRIDGE, Mass. & SINGAPORE–(BUSINESS WIRE)–Sunbird Bio, a biotechnology company developing proprietary protein- and blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced that new findings from a study evaluating the correlation between heightened levels of extracellular vesicle (EV)-bound tau in blood and the presence of tau tangles in the brain will be presented at the upcoming Tau2024 Global Conference taking place March 25-26, 2024 in Washington, D.C.
“The tau protein is an increasingly important biomarker in the diagnosis and treatment of Alzheimer’s disease and other neurological disorders,” said John McDonough, executive chair and CEO of Sunbird Bio. “Utilizing our APEX diagnostic platform, we are continuing to expand our portfolio of blood-based tests in neurological disorders such as Alzheimer’s disease and Parkinson’s disease. As part of this endeavor, it is important for us to understand the association between EV-bound tau in the blood and the presence of tau tangles in the brain.”
The accumulation of tau tangles is a hallmark pathology of Alzheimer’s disease, particularly in the later stages of the disease. Many pharmaceutical companies are developing therapeutics that specifically target this protein, but accessible and accurate detection methods are urgently needed. APEX, Sunbird Bio’s lead technology platform, is the first platform that directly detects EV-bound disease-specific proteins that aggregate in the brain. Data to date have shown it is capable of detecting another key Alzheimer’s disease protein, amyloid beta, and other proteins associated with neurological disorders.
Following are details about the poster presentation at Tau2024:
- Topic: The correlation between EV-bound tau proteins in blood and presence of tau tangles in the brain
- Presenter: Nicholas Ho, Ph.D., Head of Innovation and Scientific Co-Founder, Sunbird Bio
- Date and Time: Tuesday, March 26, 2024, 10:00AM ET – 10:45AM ET
About Sunbird Bio
Sunbird Bio is a biotechnology company developing proprietary protein- and blood-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of neurological disorders and early-stage cancer. Sunbird’s innovative technologies uniquely detect the property and activity of proteins to empower researchers and clinicians with actionable information that is not available or accessible from current tests. Sunbird Bio’s unparalleled leadership in protein- and blood-based diagnostics positions the company to become a global leader in the field, addressing significant research and clinical gaps, and serving multiple, sizable markets. For more information, please visit sunbirdbio.com.
Contacts
Laura Morgan
Sam Brown, Inc.
951.333.9110
lauramorgan@sambrown.com